

Interesting Images

Diffuse Cardiac Uptake Misdiagnosed as Cardiac Amyloidosis in Bone Scan

Yeongjoo Lee ¹, Jaehyuk Jang ² and Sae Jung Na ^{1,*}

¹ Department of Radiology, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea; soap2222@msn.com

² Division of Cardiology, Department of Internal Medicine, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea; let87@naver.com

* Correspondence: sj0405@catholic.ac.kr

Abstract: In this presented case, a 77-year-old woman with an implanted prosthesis and ongoing knee pain underwent a bone scan using ^{99m}Tc-hydroxydiphosphonate (HDP) in suspicion for bone infection. An incidental finding from this scan revealed diffuse cardiac uptake, necessitating further diagnostic procedures to exclude the possibility of cardiac amyloidosis. In the subsequent ^{99m}Tc-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) scan and SPECT images, no perceptible cardiac uptake was observed at all. Upon retrospective review of the patient's medical records, she received 1000 mg of ferric carboxymaltose for iron-deficient anemia the day before the ^{99m}Tc-HDP bone scan. Therefore, it was assumed that the diffuse and temporary cardiac activity was due to the transient iron overload. We present and share these bone scan images in order to avoid possible future misinterpretation of cardiac amyloidosis.

Keywords: bone scan; ^{99m}Tc-HDP; cardiac amyloidosis; iron overload



Citation: Lee, Y.; Jang, J.; Na, S.J.

Diffuse Cardiac Uptake

Misdiagnosed as Cardiac

Amyloidosis in Bone Scan.

Diagnostics **2023**, *13*, 3342.

[https://doi.org/10.3390/](https://doi.org/10.3390/diagnostics13213342)

[diagnostics13213342](https://doi.org/10.3390/diagnostics13213342)

Academic Editor: Consolato M. Sergi

Received: 11 October 2023

Revised: 25 October 2023

Accepted: 27 October 2023

Published: 30 October 2023



Copyright: © 2023 by the authors.

Licensee MDPI, Basel, Switzerland.

This article is an open access article

distributed under the terms and

conditions of the Creative Commons

Attribution (CC BY) license ([https://](https://creativecommons.org/licenses/by/4.0/)

[creativecommons.org/licenses/by/](https://creativecommons.org/licenses/by/4.0/)

[4.0/](https://creativecommons.org/licenses/by/4.0/)).




Figure 1. We present a 77-year-old woman who suffered ongoing left knee pain after the prosthesis insertion. To evaluate the extent and severity of the periprosthetic bone infection, a bone scan using ^{99m}Tc-hydroxydiphosphonate (HDP) was performed. Beyond the expected uptake in the left knee's periprosthetic region, an incidental finding indicated a diffuse and moderate cardiac uptake (arrow). This finding was classified as grade 2, based on the visual grading system ranging from 0 to 3, proposed by Perugini for the diagnosis of cardiac amyloidosis in bone scan [1].




Figure 2. A subsequent bone scan using ^{99m}Tc -3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) was obtained three weeks later including SPECT images for assessment of transthyretin-type cardiac amyloidosis (CA). The decision was influenced by the accumulating evidence that favored the use of ^{99m}Tc -DPD over ^{99m}Tc -HDP for detecting CA [2–4], and by the necessity of SPECT images. However, no perceptible radiotracer accumulation was observed in the subsequent ^{99m}Tc -DPD scan (A). Additionally, no perceptible radiotracer uptake was noted in the myocardium on the axial SPECT images (B,C). An echocardiogram revealed preserved ejection fraction of 60% without any abnormal wall thickness or abnormal wall motion. No abnormality was found in serum free light chain, serum and urine protein electrophoresis/immunofixation data. Upon thorough review of her medical history, her hemoglobin level was 8.7 g/dL, and she was diagnosed with iron-deficient anemia. We also observed that a total of 1000mg of ferric carboxymaltose had been intravenously administered the day before the ^{99m}Tc -HDP bone scan. Hence, it is assumed that the diffuse and temporary cardiac activity was a result of transient iron overload. Bone scan using ^{99m}Tc -DPD or ^{99m}Tc -PYP is known for its several advantages in the diagnosis in CA. They not only have high sensitivity and specificity but also provide a non-invasive, whole-body evaluation and are readily accessible [5,6]. Currently, multidisciplinary experts in cardiovascular imaging and cardiac amyloidosis recommend including bone scans for diagnosis of CA [7]. However, caution should be exercised in the interpretation of myocardial uptake in a bone scan, as altered biodistribution of radiotracer can occur in various medical conditions including iron overload [8–12]. As bone scans are widely used in the diagnosis of CA, we present and share this image in order to avoid possible future misinterpretation.

Author Contributions: Conceptualization, Y.L.; S.J.N.; methodology, Y.L.; J.J.; S.J.N.; writing—original draft preparation, Y.L.; writing—review and editing, Y.L.; J.J.; S.J.N. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki. The need for ethical review and approval was waived because of the retrospective nature of this study.

Informed Consent Statement: The IRB Board waived the need for patient consent for this retrospective single-case report.

Data Availability Statement: The data presented in this study are available upon request from the corresponding author.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Perugini, E.; Guidalotti, P.L.; Salvi, F.; Cooke, R.M.T.; Pettinato, C.; Riva, L.; Leone, O.; Farsad, M.; Ciliberti, P.; Bacchi-Reggiani, L.; et al. Noninvasive Etiologic Diagnosis of Cardiac Amyloidosis Using ^{99m}Tc -3,3-Diphosphono-1,2-Propanodicarboxylic Acid Scintigraphy. *J. Am. Coll. Cardiol.* **2005**, *46*, 1076–1084. [[CrossRef](#)] [[PubMed](#)]
2. Treglia, G.; Glaudemans, A.; Bertagna, F.; Hazenberg, B.P.C.; Erba, P.A.; Giubbini, R.; Ceriani, L.; Prior, J.O.; Giovanella, L.; Slart, R. Diagnostic accuracy of bone scintigraphy in the assessment of cardiac transthyretin-related amyloidosis: A bivariate meta-analysis. *Eur. J. Nucl. Med. Mol. Imaging* **2018**, *45*, 1945–1955. [[CrossRef](#)] [[PubMed](#)]
3. Brownrigg, J.; Lorenzini, M.; Lumley, M.; Elliott, P. Diagnostic performance of imaging investigations in detecting and differentiating cardiac amyloidosis: A systematic review and meta-analysis. *ESC Heart Fail.* **2019**, *6*, 1041–1051. [[CrossRef](#)] [[PubMed](#)]
4. de Haro-del Moral, F.J.; Sánchez-Lajusticia, A.; Gómez-Bueno, M.; García-Pavía, P.; Salas-Antón, C.; Segovia-Cubero, J. Role of cardiac scintigraphy with ^{99m}Tc -DPD in the differentiation of cardiac amyloidosis subtype. *Rev. Esp. Cardiol. (Engl. Ed.)* **2012**, *65*, 440–446. [[CrossRef](#)] [[PubMed](#)]
5. Bokhari, S.; Castaño, A.; Pozniakoff, T.; Deslisle, S.; Latif, F.; Maurer, M.S. (^{99m}Tc)-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. *Circ. Cardiovasc. Imaging* **2013**, *6*, 195–201. [[CrossRef](#)] [[PubMed](#)]
6. Rapezzi, C.; Quarta, C.C.; Guidalotti, P.L.; Pettinato, C.; Fanti, S.; Leone, O.; Ferlini, A.; Longhi, S.; Lorenzini, M.; Reggiani, L.B.; et al. Role of (^{99m}Tc)-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. *JACC Cardiovasc. Imaging* **2011**, *4*, 659–670. [[CrossRef](#)] [[PubMed](#)]
7. Dorbala, S.; Ando, Y.; Bokhari, S.; Dispenzieri, A.; Falk, R.H.; Ferrari, V.A.; Fontana, M.; Gheysens, O.; Gillmore, J.D.; Glaudemans, A.; et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2-Diagnostic Criteria and Appropriate Utilization. *J. Card. Fail.* **2019**, *25*, 854–865. [[CrossRef](#)] [[PubMed](#)]
8. Shin, E.; Oh, M.; Sung, C.; Kim, K.H.; Ryu, J.S. Altered Biodistribution of (^{99m}Tc)-DPD on Bone Scan After Intravenous Iron Supplement. *Nucl. Med. Mol. Imaging* **2017**, *51*, 347–349. [[CrossRef](#)] [[PubMed](#)]
9. Choy, D.; Murray, I.P.; Hoschl, R. The effect of iron on the biodistribution of bone scanning agents in humans. *Radiology* **1981**, *140*, 197–202. [[CrossRef](#)] [[PubMed](#)]
10. Byun, H.H.; Rodman, S.G.; Chung, K.E. Soft-tissue concentration of ^{99m}Tc -phosphates associated with injections of iron dextran complex. *J. Nucl. Med.* **1976**, *17*, 374–375. [[PubMed](#)]
11. Parker, J.A.; Jones, A.G.; Davis, M.A.; Mcilmoyle, G.; Tow, D.E. Reduced uptake of bone-seeking radiopharmaceuticals related to iron excess. *Clin. Nucl. Med.* **1976**, *1*, 267–268. [[CrossRef](#)]
12. Forauer, A.R.; Grossman, S.J.; Joyce, J.M. Altered biodistribution of Tc- 99m HMDP on bone scintigraphy from recent intravenous iron therapy. *Clin. Nucl. Med.* **1994**, *19*, 817–818. [[CrossRef](#)] [[PubMed](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.